Accéder au contenu
Merck

Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin.

Diabetes research and clinical practice (2018-07-22)
Gerd Luippold, Michael Mark, Thomas Klein, Kerstin Amann, Christoph Daniel
RÉSUMÉ

The two dipeptidyl peptidase (DPP)-4 inhibitors, linagliptin and sitagliptin, were shown to exert different binding kinetics in vitro. Twenty-four hours after oral dosing particularly in vivo inhibition of renal-specific DPP-4 activity was more sustained in Sprague Dawley rats after exposure to linagliptin than it was after sitagliptin.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Gly-Pro 4-methoxy-β-naphthylamide, dipeptidylpeptidase IV substrate